<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">J Bras Pneumol</journal-id>
      <journal-id journal-id-type="iso-abbrev">J Bras Pneumol</journal-id>
      <journal-title-group>
        <journal-title>Jornal Brasileiro de Pneumologia</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1806-3713</issn>
      <issn pub-type="epub">1806-3756</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Pneumologia e Tisiologia</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">24626274</article-id>
      <article-id pub-id-type="pmc">4075924</article-id>
      <article-id pub-id-type="publisher-id">S1806-37132014000100077</article-id>
      <article-id pub-id-type="doi">10.1590/S1806-37132014000100012</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Adalimumab-induced acute interstitial lung disease in a patient with
rheumatoid arthritis<xref ref-type="fn" rid="fn01">*</xref>
</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Dias</surname>
            <given-names>Ol&#xED;via Meira</given-names>
          </name>
          <role>Collaborating Physician</role>
          <aff>Department of Pulmonology, Heart Institute, University of S&#xE3;o Paulo School of
Medicine Hospital das Cl&#xED;nicas, S&#xE3;o Paulo, Brazil</aff>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pereira</surname>
            <given-names>Daniel Antunes Silva</given-names>
          </name>
          <role>Collaborating Physician</role>
          <aff>Department of Pulmonology, Heart Institute, University of S&#xE3;o Paulo School of
Medicine Hospital das Cl&#xED;nicas, S&#xE3;o Paulo, Brazil</aff>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Baldi</surname>
            <given-names>Bruno Guedes</given-names>
          </name>
          <role>Attending Physician</role>
          <aff>Department of Pulmonology, Heart Institute, University of S&#xE3;o Paulo School of
Medicine Hospital das Cl&#xED;nicas, S&#xE3;o Paulo, Brazil</aff>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Costa</surname>
            <given-names>Andr&#xE9; Nathan</given-names>
          </name>
          <role>Attending Physician</role>
          <aff>Department of Pulmonology, Heart Institute, University of S&#xE3;o Paulo School of
Medicine Hospital das Cl&#xED;nicas, S&#xE3;o Paulo, Brazil</aff>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Athanazio</surname>
            <given-names>Rodrigo Abensur</given-names>
          </name>
          <role>Attending Physician</role>
          <aff>Department of Pulmonology, Heart Institute, University of S&#xE3;o Paulo School of
Medicine Hospital das Cl&#xED;nicas, S&#xE3;o Paulo, Brazil</aff>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kairalla</surname>
            <given-names>Ronaldo Adib</given-names>
          </name>
          <role>Associate Professor</role>
          <aff>Department of Pulmonology, Heart Institute, University of S&#xE3;o Paulo School of
Medicine Hospital das Cl&#xED;nicas, S&#xE3;o Paulo, Brazil</aff>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Carvalho</surname>
            <given-names>Carlos Roberto Ribeiro</given-names>
          </name>
          <role>Full Professor</role>
          <aff>Department of Pulmonology, Heart Institute, University of S&#xE3;o Paulo School of
Medicine Hospital das Cl&#xED;nicas, S&#xE3;o Paulo, Brazil</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <corresp id="c01"><bold>Correspondence to:</bold> Ol&#xED;via Meira Dias Rua Capote Valente, 671, apto.
1401, Pinheiros CEP 05409-002, S&#xE3;o Paulo, SP, Brasil Tel. 55 11 3069-5000. E-mail:
<email>meiradias@yahoo.com.br</email></corresp>
        <fn fn-type="financial-disclosure">
          <p>Financial support: None.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <season>Jan-Feb</season>
        <year>2014</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <season>Jan-Feb</season>
        <year>2014</year>
      </pub-date>
      <volume>40</volume>
      <issue>1</issue>
      <fpage>77</fpage>
      <lpage>81</lpage>
      <history>
        <date date-type="received">
          <day>09</day>
          <month>11</month>
          <year>2012</year>
        </date>
        <date date-type="accepted">
          <day>25</day>
          <month>1</month>
          <year>2013</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution Non-Commercial License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>The use of immunobiological agents for the treatment of autoimmune diseases is
increasing in medical practice. Anti-TNF therapies have been increasingly used in
refractory autoimmune diseases, especially rheumatoid arthritis, with promising
results. However, the use of such therapies has been associated with an increased
risk of developing other autoimmune diseases. In addition, the use of anti-TNF agents
can cause pulmonary complications, such as reactivation of mycobacterial and fungal
infections, as well as sarcoidosis and other interstitial lung diseases (ILDs). There
is evidence of an association between ILD and the use of anti-TNF agents, etanercept
and infliximab in particular. Adalimumab is the newest drug in this class, and some
authors have suggested that its use might induce or exacerbate preexisting ILDs. In
this study, we report the first case of acute ILD secondary to the use of adalimumab
in Brazil, in a patient with rheumatoid arthritis and without a history of ILD.</p>
      </abstract>
      <kwd-group>
        <kwd>Lung diseases, interstitial</kwd>
        <kwd>Arthritis, rheumatoid</kwd>
        <kwd>Antirheumatic agents</kwd>
        <kwd>Antibodies, monoclonal, humanized/adverse effects</kwd>
      </kwd-group>
      <counts>
        <fig-count count="2"/>
        <ref-count count="16"/>
        <page-count count="5"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>Introduction</title>
      <p>The use of immunobiological agents for the treatment of autoimmune diseases is
increasing in medical practice. Anti-TNF therapies and therapies with B-cell-depleting
agents (rituximab) have been increasingly used in refractory autoimmune diseases,
especially rheumatoid arthritis (RA), systemic sclerosis, and systemic lupus
erythematosus, with promising results. The TNF is an interleukin secreted by activated
macrophages and T cells as a common pathway in a series of inflammatory, autoimmune, or
neoplastic responses; its blockade, whether in the form of blockade of its receptors or
in the form of soluble antibodies, decreases adhesion molecule expression on the
endothelial surface, decreases leukocyte migration, and inhibits the production of other
inflammatory cytokines. However, the use of such therapies has been associated with an
increased risk of developing other autoimmune diseases, such as systemic lupus
erythematosus, autoimmune hepatitis, thyroiditis, and cutaneous vasculitis. According to
the literature, the use of anti-TNF agents particularly in the lung is little effective
in controlling interstitial lung disease (ILD) secondary to collagenosis, and can lead
to other complications, such as reactivation of mycobacterial and fungal infections, as
well as sarcoidosis and other ILDs.<sup>(</sup><xref rid="B01" ref-type="bibr"><sup>1</sup></xref><sup>)</sup>
</p>
      <p>There is evidence of an association between ILD and the use of anti-TNF agents,
etanercept and infliximab in particular.<sup>(</sup><xref rid="B02" ref-type="bibr"><sup>2</sup></xref><sup>)</sup> Adalimumab is the newest drug in this class, and,
because it is a humanized monoclonal antibody, it would have the potential advantage of
being less immunogenic than its precursors. However, although adalimumab is infrequently
used, some authors have suggested that its use might induce or exacerbate preexisting
ILDs.<sup>(</sup><xref rid="B03" ref-type="bibr"><sup>3</sup></xref><sup>-</sup><xref rid="B09" ref-type="bibr"><sup>9</sup></xref><sup>)</sup>
</p>
      <p>The objective of the present study was to report the first case of acute ILD secondary
to the use of adalimumab in Brazil, in a patient with RA and without a history of
ILD.</p>
    </sec>
    <sec>
      <title>Case report</title>
      <p>A 62-year-old female patient with a 20-year history of RA had been on methotrexate,
leflunomide, and prednisone. Because the articular inflammatory process persisted, we
decided to start the patient on adalimumab, continuing her on methotrexate. A chest
X-ray showed no changes suggestive of previous tuberculosis or signs of incipient ILD;
and the intradermal (PPD) test for tuberculosis was negative (0 mm). One week after
receiving the second dose of adalimumab (40 mg weekly), the patient started experiencing
dry cough, dyspnea on moderate exertion, and daily fever (38&#xB0;C). At that point, the
results of chest X-ray, physical examination, and laboratory tests, including blood
workup, were normal-hemoglobin, 13.1 g/dL; hematocrit, 39.2%; 8,380 leukocytes (75%
neutrophils, 0.4% eosinophil, 9.8% lymphocytes); and 355,000 platelets, except for an
increase in inflammatory markers (C-reactive protein, 326 mg/dL; reference value &lt; 3
mg/dL) and in ESR (67 mm, reference value &lt; 20.2 mm). Sputum smears for AFB and blood
cultures were negative. The patient was started on empiric treatment with levofloxacin;
however, she continued to have fever and dyspnea. A HRCT scan of the chest, performed
two weeks after symptom onset, revealed ground-glass opacities, predominantly in the
upper and middle lung fields, associated with areas of smooth interlobular septal
thickening (<xref ref-type="fig" rid="f01">Figure 1</xref>). Therefore, a presumptive
diagnosis of ILD secondary to the use of adalimumab was made. We decided to discontinue
the patient from the anti-TNF agent and methotrexate and to continue her on low-dose
prednisone (5 mg/day). The patient showed progressive reduction in dyspnea, remission of
fever, and normalization of inflammatory markers, without reactivation of the articular
inflammatory process. Three weeks after the onset of the condition, the results of
physical examination and spirometry were normal, with an SpO<sub>2</sub> of 98% on room
air. A second HRCT, performed three weeks after symptom onset, showed near-complete
resolution of the ground-glass areas (<xref ref-type="fig" rid="f02">Figure
2</xref>).</p>
      <p>
<fig id="f01" orientation="portrait" position="float"><label>Figure 1</label><caption><title>HRCT scan of the chest showing pulmonary ground-glass opacities,
predominantly in the upper lobes, in A, and in the central regions, in B,
associated with areas of smooth interlobular septal thickening
(arrows).</title></caption><graphic xlink:href="1806-3713-jbpneu-40-01-00077-gf01"/></fig>
</p>
      <p>
<fig id="f02" orientation="portrait" position="float"><label>Figure 2</label><caption><title>HRCT scan of the chest performed three weeks after the onset of the
condition. A comparative analysis of the slices shows significant spontaneous
improvement in the ground-glass opacities, in relation to the first scan, in
the upper lung fields, in A, and at the level of the main carina, in B. There
remain faint ground-glass opacities together with slight reticular infiltrates
in the subpleural regions, predominantly in the right hemithorax, especially in
the middle lobe.</title></caption><graphic xlink:href="1806-3713-jbpneu-40-01-00077-gf02"/></fig>
</p>
    </sec>
    <sec sec-type="discussion">
      <title>Discussion</title>
      <p>The pathogenesis of anti-TNF-agent-induced lung injury remains unknown; TNF is believed
to exert a pro-fibrotic action by stimulating collagen synthesis by fibroblasts and
myofibroblasts.<sup>(</sup><xref rid="B10" ref-type="bibr"><sup>10</sup></xref><sup>)</sup> In addition, an increased Th2-type lymphocyte
response,<sup>(</sup><xref rid="B07" ref-type="bibr"><sup>7</sup></xref><sup>)</sup>
the action of IFN-&#x3B3; unopposed by TNF,<sup>(</sup><xref rid="B07" ref-type="bibr"><sup>7</sup></xref><sup>)</sup> and the synergistic action of methotrexate are
speculated to play a role in the development of lung injury.<sup>(</sup><xref rid="B08" ref-type="bibr"><sup>8</sup></xref><sup>,</sup><xref rid="B09" ref-type="bibr"><sup>9</sup></xref><sup>,</sup><xref rid="B11" ref-type="bibr"><sup>11</sup></xref><sup>,</sup><xref rid="B12" ref-type="bibr"><sup>12</sup></xref><sup>)</sup>
</p>
      <p>Clinical findings are nonspecific, and include dry cough, fever, and
dyspnea,<sup>(</sup><xref rid="B02" ref-type="bibr"><sup>2</sup></xref><sup>)</sup>
which can be progressive or more intense after each administration of the
medication.<sup>(</sup><xref rid="B06" ref-type="bibr"><sup>6</sup></xref><sup>)</sup> Symptoms can appear from one month<sup>(</sup><xref rid="B09" ref-type="bibr"><sup>9</sup></xref><sup>)</sup> to three and a half years
after treatment initiation.<sup>(</sup><xref rid="B07" ref-type="bibr"><sup>7</sup></xref><sup>)</sup> Findings on HRCT can include ground-glass opacities,
foci of consolidation, reticulated patterns, and traction
bronchiectasis.<sup>(</sup><xref rid="B06" ref-type="bibr"><sup>6</sup></xref><sup>,</sup><xref rid="B08" ref-type="bibr"><sup>8</sup></xref><sup>)</sup>
</p>
      <p>Attributing lung injury to drugs and, in the present case, to anti-TNF agents is a
challenge. The diagnosis is usually presumptive, and the causal connection is determined
by temporal association between drug initiation and symptom onset and by improvement
after drug discontinuation, always after excluding other etiologies. In such patients,
in the context of immunosuppression, infection should be considered as an important
differential. <sup>(</sup><xref rid="B13" ref-type="bibr"><sup>13</sup></xref><sup>)</sup> It should be borne in mind that the use of
adalimumab has been associated with cases of pulmonary cryptococcosis<sup>(</sup><xref rid="B14" ref-type="bibr"><sup>14</sup></xref><sup>)</sup> and disseminated
mycobacteriosis.<sup>(</sup><xref rid="B15" ref-type="bibr"><sup>15</sup></xref><sup>)</sup> In this clinical context, diffuse ground-glass
opacities associated with intralobular septal thickening should also lead to the
exclusion of other etiologies, such as viral infections or infections with
<italic>Pneumocystis jiroveci</italic>,<sup>(</sup><xref rid="B16" ref-type="bibr"><sup>16</sup></xref><sup>)</sup> alveolar hemorrhage, pulmonary congestion, and
drug toxicity due to concomitant treatment with methotrexate. Bronchoscopy and
bronchoalveolar lavage aid in the differential diagnosis.</p>
      <p>In the largest sample of patients with lung injury secondary to anti-TNF therapy, 122
cases were reported (3 of which were secondary to adalimumab). The mean time to symptom
onset was 26 weeks. The most common histological patterns were usual interstitial
pneumonia, organizing pneumonia, diffuse alveolar damage, and even lymphocytic
interstitial pneumonia. Of the cases that were followed up until the outcome was known,
40% experienced improvement in ILD, 25% had partial resolution of ILD, and 35% had no
resolution of ILD, with death occurring in 29% of the patients. Predictors of poor
prognosis were age &gt; 65 years, late onset of symptoms, frequent use of other
immunosuppressants (especially methotrexate), and a previous diagnosis of
ILD.<sup>(</sup><xref rid="B02" ref-type="bibr"><sup>2</sup></xref><sup>)</sup>
Despite an isolated report of improvement in ILD with the use of this medication for
RA,<sup>(</sup><xref rid="B09" ref-type="bibr"><sup>9</sup></xref><sup>)</sup> it is
currently recommended that adalimumab and other anti-TNF drugs should not be
contraindicated in patients with preexisting ILD or other lung diseases but that caution
should be exerted.<sup>(</sup><xref rid="B01" ref-type="bibr"><sup>1</sup></xref><sup>-</sup><xref rid="B03" ref-type="bibr"><sup>3</sup></xref><sup>,</sup><xref rid="B10" ref-type="bibr"><sup>10</sup></xref><sup>)</sup>
</p>
      <p>The course of cases of adalimumab-induced ILD can vary from complete remission after
drug discontinuation alone to treatment refractoriness,<sup>(</sup><xref rid="B02" ref-type="bibr"><sup>2</sup></xref><sup>,</sup><xref rid="B06" ref-type="bibr"><sup>6</sup></xref><sup>)</sup> with rapid progression to death. <sup>(</sup><xref rid="B03" ref-type="bibr"><sup>3</sup></xref>
<sup>)</sup> The use of corticosteroids or intravenous immunoglobulin, or both, should
be considered in selected cases. Because of the potential severity of the patient's
condition, we decided in favor of CT follow-up, with scans being performed within a
short interval of each other despite the resulting radiation load.</p>
      <p>Once it is confirmed that drug reaction has occurred, it is not recommended that the
drug be reintroduced or even replaced with another drug belonging to the same class of
anti-TNF agents.<sup>(</sup><xref rid="B02" ref-type="bibr"><sup>2</sup></xref><sup>,</sup><xref rid="B10" ref-type="bibr"><sup>10</sup></xref><sup>)</sup> Therefore, adalimumab, like other anti-TNF drugs,
should always be considered in the list of drugs potentially causing lung injury.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn id="fn01" fn-type="supported-by">
        <label>*</label>
        <p> Study carried out in the Department of Pulmonology, Heart Institute, University of
S&#xE3;o Paulo School of Medicine <italic>Hospital das Cl&#xED;nicas</italic>, S&#xE3;o Paulo,
Brazil.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="B01">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ramos-Casals</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Brito-Zer&#xF3;n</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Soto</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Cuadrado</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Khamashta</surname>
              <given-names>MA</given-names>
            </name>
          </person-group>
          <article-title>Autoimmune diseases induced by TNF-targeted
therapies</article-title>
          <source>Best Pract Res Clin Rheumatol</source>
          <year>2008</year>
          <volume>22</volume>
          <issue>5</issue>
          <fpage>847</fpage>
          <lpage>861</lpage>
          <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.berh.2008.09.008">http://dx.doi.org/10.1016/j.berh.2008.09.008</ext-link>
          <pub-id pub-id-type="pmid">19028367</pub-id>
        </element-citation>
      </ref>
      <ref id="B02">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Perez-Alvarez</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Perez-de-Lis</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Diaz-Lagares</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Pego-Reigosa</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Retamozo</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Bove</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Interstitial lung disease induced or exacerbated by
TNF-targeted therapies: analysis of 122 cases</article-title>
          <source>Semin Arthritis Rheum</source>
          <year>2011</year>
          <volume>41</volume>
          <issue>2</issue>
          <fpage>256</fpage>
          <lpage>264</lpage>
          <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.semarthrit.2010.11.002">http://dx.doi.org/10.1016/j.semarthrit.2010.11.002</ext-link>
          <pub-id pub-id-type="pmid">21277618</pub-id>
        </element-citation>
      </ref>
      <ref id="B03">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Allanore</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Devos-Fran&#xE7;ois</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Caramella</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Boumier</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Jounieaux</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Kahan</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Fatal exacerbation of fibrosing alveolitis associated
with systemic sclerosis in a patient treated with adalimumab</article-title>
          <source>Ann Rheum Dis</source>
          <year>2006</year>
          <volume>65</volume>
          <issue>6</issue>
          <fpage>834</fpage>
          <lpage>835</lpage>
          <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1136/ard.2005.044453">http://dx.doi.org/10.1136/ard.2005.044453</ext-link>
          <!--<pub-id pub-id-type="pmcid">1798181</pub-id>-->
          <pub-id pub-id-type="pmid">16699057</pub-id>
        </element-citation>
      </ref>
      <ref id="B04">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Huggett</surname>
              <given-names>MT</given-names>
            </name>
            <name>
              <surname>Armstrong</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Adalimumab-associated pulmonary fibrosis</article-title>
          <source>Rheumatology (Oxford)</source>
          <year>2006</year>
          <volume>45</volume>
          <issue>10</issue>
          <fpage>1312</fpage>
          <lpage>1313</lpage>
          <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/rheumatology/kel220">http://dx.doi.org/10.1093/rheumatology/kel220</ext-link>
          <pub-id pub-id-type="pmid">16935921</pub-id>
        </element-citation>
      </ref>
      <ref id="B05">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schoe</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>van der Laan-Baalbergen</surname>
              <given-names>NE</given-names>
            </name>
            <name>
              <surname>Huizinga</surname>
              <given-names>TW</given-names>
            </name>
            <name>
              <surname>Breedveld</surname>
              <given-names>FC</given-names>
            </name>
            <name>
              <surname>van Laar</surname>
              <given-names>JM</given-names>
            </name>
          </person-group>
          <article-title>Pulmonary fibrosis in a patient with rheumatoid
arthritis treated with adalimumab</article-title>
          <source>Arthritis Rheum</source>
          <year>2006</year>
          <volume>55</volume>
          <issue>1</issue>
          <fpage>157</fpage>
          <lpage>159</lpage>
          <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/art.21716">http://dx.doi.org/10.1002/art.21716</ext-link>
          <pub-id pub-id-type="pmid">16463430</pub-id>
        </element-citation>
      </ref>
      <ref id="B06">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yamazaki</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Isogai</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Sakurai</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Nagasaka</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>A case of adalimumab-associated interstitial pneumonia
with rheumatoid arthritis</article-title>
          <source>Mod Rheumatol</source>
          <year>2010</year>
          <volume>20</volume>
          <issue>5</issue>
          <fpage>518</fpage>
          <lpage>521</lpage>
          <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s10165-010-0308-4">http://dx.doi.org/10.1007/s10165-010-0308-4</ext-link>
          <pub-id pub-id-type="pmid">20467775</pub-id>
        </element-citation>
      </ref>
      <ref id="B07">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dascalu</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Mrejen-Shakin</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Bandagi</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Adalimumab-induced acute pneumonitis in a patient with
rheumatoid arthritis</article-title>
          <source>J Clin Rheumatol</source>
          <year>2010</year>
          <volume>16</volume>
          <issue>4</issue>
          <fpage>172</fpage>
          <lpage>174</lpage>
          <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/RHU.0b013e3181df8361">http://dx.doi.org/10.1097/RHU.0b013e3181df8361</ext-link>
          <pub-id pub-id-type="pmid">20511978</pub-id>
        </element-citation>
      </ref>
      <ref id="B08">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Reid</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Bressler</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>English</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>A case of adalimumab-induced pneumonitis in a
45-year-old man with Crohn's disease</article-title>
          <source>Can Respir J</source>
          <year>2011</year>
          <volume>18</volume>
          <issue>5</issue>
          <fpage>262</fpage>
          <lpage>264</lpage>
          <!--<pub-id pub-id-type="pmcid">3267602</pub-id>-->
          <pub-id pub-id-type="pmid">21969926</pub-id>
        </element-citation>
      </ref>
      <ref id="B09">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Komiya</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Ishii</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Fujita</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Oka</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Iwata</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Sonoda</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Adalimumab-induced interstitial pneumonia with an
improvement of pre-existing rheumatoid arthritis-associated lung
involvement</article-title>
          <source>Intern Med</source>
          <year>2011</year>
          <volume>50</volume>
          <issue>7</issue>
          <fpage>749</fpage>
          <lpage>751</lpage>
          <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.2169/internalmedicine.50.4748">http://dx.doi.org/10.2169/internalmedicine.50.4748</ext-link>
          <pub-id pub-id-type="pmid">21467710</pub-id>
        </element-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Panopoulos</surname>
              <given-names>ST</given-names>
            </name>
            <name>
              <surname>Sfikakis</surname>
              <given-names>PP</given-names>
            </name>
          </person-group>
          <article-title>Biological treatments and connective tissue disease
associated interstitial lung disease</article-title>
          <source>Curr Opin Pulm Med</source>
          <year>2011</year>
          <volume>17</volume>
          <issue>5</issue>
          <fpage>362</fpage>
          <lpage>367</lpage>
          <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/MCP.0b013e3283483ea5">http://dx.doi.org/10.1097/MCP.0b013e3283483ea5</ext-link>
          <pub-id pub-id-type="pmid">21597375</pub-id>
        </element-citation>
      </ref>
      <ref id="B11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Thavarajah</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Rhew</surname>
              <given-names>EJ</given-names>
            </name>
            <name>
              <surname>Yeldandi</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>Kamp</surname>
              <given-names>DW</given-names>
            </name>
          </person-group>
          <article-title>Pulmonary complications of tumor necrosis
factor-targeted therapy</article-title>
          <source>Respir Med</source>
          <year>2009</year>
          <volume>103</volume>
          <issue>5</issue>
          <fpage>661</fpage>
          <lpage>669</lpage>
          <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.rmed.2009.01.002">http://dx.doi.org/10.1016/j.rmed.2009.01.002</ext-link>
          <!--<pub-id pub-id-type="pmcid">2743303</pub-id>-->
          <pub-id pub-id-type="pmid">19201589</pub-id>
        </element-citation>
      </ref>
      <ref id="B12">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Golden</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Katz</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Balk</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Golden</surname>
              <given-names>HE</given-names>
            </name>
          </person-group>
          <article-title>The relationship of preexisting lung disease to the
development of methotrexate pneumonitis in patients with rheumatoid
arthritis</article-title>
          <source>J Rheumatol</source>
          <year>1995</year>
          <volume>22</volume>
          <issue>6</issue>
          <fpage>1043</fpage>
          <lpage>1047</lpage>
          <pub-id pub-id-type="pmid">7674228</pub-id>
        </element-citation>
      </ref>
      <ref id="B13">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Baldi</surname>
              <given-names>BG</given-names>
            </name>
            <name>
              <surname>Pereira</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Rubin</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Santana</surname>
              <given-names>AN</given-names>
            </name>
            <name>
              <surname>Costa</surname>
              <given-names>AN</given-names>
            </name>
            <name>
              <surname>Carvalho</surname>
              <given-names>CR</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Highlights of the Brazilian Thoracic Association
guidelines for interstitial lung diseases</article-title>
          <source>J Bras Pneumol</source>
          <year>2012</year>
          <volume>38</volume>
          <issue>3</issue>
          <fpage>282</fpage>
          <lpage>291</lpage>
          <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1590/S1806-37132012000300002">http://dx.doi.org/10.1590/S1806-37132012000300002</ext-link>
          <pub-id pub-id-type="pmid">22782597</pub-id>
        </element-citation>
      </ref>
      <ref id="B14">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Iwata</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Nagano</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Tomita</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Suehiro</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Nakatsuka</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kimura</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Adalimumab-associated pulmonary
cryptococcosis</article-title>
          <source>Ann Thorac Cardiovasc Surg</source>
          <year>2011</year>
          <volume>17</volume>
          <issue>4</issue>
          <fpage>390</fpage>
          <lpage>393</lpage>
          <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.5761/atcs.cr.10.01561">http://dx.doi.org/10.5761/atcs.cr.10.01561</ext-link>
          <pub-id pub-id-type="pmid">21881327</pub-id>
        </element-citation>
      </ref>
      <ref id="B15">
        <label>15</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yoo</surname>
              <given-names>WH</given-names>
            </name>
          </person-group>
          <article-title>Multiple organ tuberculosis of lung, pleura, and
peritoneum in ankylosing spondylitis during adalimumab therapy</article-title>
          <source>Rheumatol Int</source>
          <year>2012</year>
          <volume>32</volume>
          <issue>3</issue>
          <fpage>787</fpage>
          <lpage>790</lpage>
          <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s00296-009-1357-x">http://dx.doi.org/10.1007/s00296-009-1357-x</ext-link>
          <pub-id pub-id-type="pmid">20049444</pub-id>
        </element-citation>
      </ref>
      <ref id="B16">
        <label>16</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kameda</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Tokuda</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Sakai</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Johkoh</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Mori</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Yoshida</surname>
              <given-names>Y</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Clinical and radiological features of acute-onset
diffuse interstitial lung diseases in patients with rheumatoid arthritis receiving
treatment with biological agents: importance of Pneumocystis pneumonia in Japan
revealed by a multicenter study</article-title>
          <source>Intern Med</source>
          <year>2011</year>
          <volume>50</volume>
          <issue>4</issue>
          <fpage>305</fpage>
          <lpage>313</lpage>
          <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.2169/internalmedicine.50.4508">http://dx.doi.org/10.2169/internalmedicine.50.4508</ext-link>
          <pub-id pub-id-type="pmid">21325762</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article id="S01" article-type="translation" xml:lang="pt">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Relato de Caso</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Doen&#xE7;a pulmonar intersticial aguda induzida por adalimumabe em paciente
com artrite reumatoide<xref ref-type="fn" rid="fn02">*</xref>
</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Dias</surname>
            <given-names>Ol&#xED;via Meira</given-names>
          </name>
          <role>M&#xE9;dica Colaboradora</role>
          <aff>Divis&#xE3;o de Pneumologia, Instituto do Cora&#xE7;&#xE3;o, Hospital das Cl&#xED;nicas, Faculdade
de Medicina da Universidade de S&#xE3;o Paulo, S&#xE3;o Paulo (SP) Brasil</aff>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pereira</surname>
            <given-names>Daniel Antunes Silva</given-names>
          </name>
          <role>M&#xE9;dico Colaborador</role>
          <aff>Divis&#xE3;o de Pneumologia, Instituto do Cora&#xE7;&#xE3;o, Hospital das Cl&#xED;nicas, Faculdade
de Medicina da Universidade de S&#xE3;o Paulo, S&#xE3;o Paulo (SP) Brasil</aff>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Baldi</surname>
            <given-names>Bruno Guedes</given-names>
          </name>
          <role>M&#xE9;dico Assistente</role>
          <aff>Divis&#xE3;o de Pneumologia, Instituto do Cora&#xE7;&#xE3;o, Hospital das Cl&#xED;nicas, Faculdade
de Medicina da Universidade de S&#xE3;o Paulo, S&#xE3;o Paulo (SP) Brasil</aff>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Costa</surname>
            <given-names>Andr&#xE9; Nathan</given-names>
          </name>
          <role>M&#xE9;dico Assistente</role>
          <aff>Divis&#xE3;o de Pneumologia, Instituto do Cora&#xE7;&#xE3;o, Hospital das Cl&#xED;nicas, Faculdade
de Medicina da Universidade de S&#xE3;o Paulo, S&#xE3;o Paulo (SP) Brasil</aff>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Athanazio</surname>
            <given-names>Rodrigo Abensur</given-names>
          </name>
          <role>M&#xE9;dico Assistente</role>
          <aff>Divis&#xE3;o de Pneumologia, Instituto do Cora&#xE7;&#xE3;o, Hospital das Cl&#xED;nicas, Faculdade
de Medicina da Universidade de S&#xE3;o Paulo, S&#xE3;o Paulo (SP) Brasil</aff>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kairalla</surname>
            <given-names>Ronaldo Adib</given-names>
          </name>
          <role>Professor Associado</role>
          <aff>Divis&#xE3;o de Pneumologia, Instituto do Cora&#xE7;&#xE3;o, Hospital das Cl&#xED;nicas, Faculdade
de Medicina da Universidade de S&#xE3;o Paulo, S&#xE3;o Paulo (SP) Brasil</aff>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Carvalho</surname>
            <given-names>Carlos Roberto Ribeiro</given-names>
          </name>
          <role>Professor Titular</role>
          <aff>Divis&#xE3;o de Pneumologia, Instituto do Cora&#xE7;&#xE3;o, Hospital das Cl&#xED;nicas, Faculdade
de Medicina da Universidade de S&#xE3;o Paulo, S&#xE3;o Paulo (SP) Brasil</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <corresp id="c02"><bold>Endere&#xE7;o para correspond&#xEA;ncia:</bold> Ol&#xED;via Meira Dias. Rua Capote Valente,
671, apto. 1401, Pinheiros CEP 05409-002, S&#xE3;o Paulo, SP, Brasil Tel. 55 11 3069-5000
E-mail: <email>meiradias@yahoo.com.br</email></corresp>
        <fn fn-type="financial-disclosure">
          <p>Apoio financeiro: Nenhum.</p>
        </fn>
      </author-notes>
      <abstract>
        <p>O uso de imunobiol&#xF3;gicos no tratamento das doen&#xE7;as autoimunes &#xE9; cada vez mais
frequente na pr&#xE1;tica m&#xE9;dica. Terapias anti-TNF t&#xEA;m sido cada vez mais utilizadas nas
doen&#xE7;as autoimunes refrat&#xE1;rias, especialmente na artrite reumatoide, com resultados
promissores. Entretanto, o uso dessas terapias est&#xE1; relacionado ao aumento do risco
do desenvolvimento de outras doen&#xE7;as autoimunes. Adicionalmente, o uso de agentes
anti-TNF pode determinar repercuss&#xF5;es pulmonares, como a reativa&#xE7;&#xE3;o de infec&#xE7;&#xF5;es por
micobact&#xE9;rias e fungos e o desenvolvimento de sarcoidose e de outras doen&#xE7;as
pulmonares intersticiais (DPIs). A associa&#xE7;&#xE3;o de DPI e uso dos agentes anti-TNF, em
especial infliximabe e etanercepte, j&#xE1; foi descrita. O adalimumabe &#xE9; a mais nova
droga dessa classe, e algumas publica&#xE7;&#xF5;es sugerem que seu uso pode determinar a
indu&#xE7;&#xE3;o ou mesmo a exacerba&#xE7;&#xE3;o de DPIs preexistentes. Neste estudo, relatamos o
primeiro caso de DPI aguda secund&#xE1;ria &#xE0; utiliza&#xE7;&#xE3;o de adalimumabe, em uma paciente
portadora de artrite reumatoide sem DPI pr&#xE9;via no Brasil.</p>
      </abstract>
      <kwd-group>
        <kwd>Doen&#xE7;as pulmonares intersticiais</kwd>
        <kwd>Artrite reumatoide</kwd>
        <kwd>Antirreum&#xE1;ticos</kwd>
        <kwd>Anticorpos monoclonais humanizados/efeitos adversos</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <sec>
        <title>Introdu&#xE7;&#xE3;o</title>
        <p>O uso de imunobiol&#xF3;gicos no tratamento das doen&#xE7;as autoimunes &#xE9; cada vez mais
frequente na pr&#xE1;tica m&#xE9;dica. Terapias anti-TNF e terapias com agentes depletores de
c&#xE9;lulas B (rituximabe) t&#xEA;m sido cada vez mais utilizadas nas doen&#xE7;as autoimunes
refrat&#xE1;rias, especialmente na artrite reumatoide (AR), esclerose sist&#xEA;mica e l&#xFA;pus
eritematoso sist&#xEA;mico, com resultados promissores. O TNF &#xE9; uma interleucina secretada
por macr&#xF3;fagos ativados e c&#xE9;lulas T como via comum em uma s&#xE9;rie de respostas
inflamat&#xF3;rias, autoimunes ou neopl&#xE1;sicas; seu bloqueio, seja na forma de bloqueio de
seus receptores ou na forma de anticorpos sol&#xFA;veis, diminui a express&#xE3;o de mol&#xE9;culas
de ades&#xE3;o na superf&#xED;cie endotelial dos &#xF3;rg&#xE3;os alvo, diminui a migra&#xE7;&#xE3;o leucocit&#xE1;ria e
inibe a produ&#xE7;&#xE3;o de outras citocinas inflamat&#xF3;rias. Entretanto, o uso dessas terapias
est&#xE1; relacionado ao aumento do risco do desenvolvimento de outras doen&#xE7;as autoimunes,
como l&#xFA;pus eritematoso sist&#xEA;mico, hepatite autoimune, tireoidites e vasculites
cut&#xE2;neas. Na literatura, o uso de agentes anti-TNF particularmente no pulm&#xE3;o &#xE9; pouco
eficaz no controle da doen&#xE7;a pulmonar intersticial (DPI) secund&#xE1;ria &#xE0; colagenose,
podendo levar a outras complica&#xE7;&#xF5;es, como a reativa&#xE7;&#xE3;o de infec&#xE7;&#xF5;es por micobact&#xE9;rias
e fungos, desenvolvimento de sarcoidose e de outras DPIs.<sup>(</sup><xref rid="B01" ref-type="bibr"><sup>1</sup></xref><sup>)</sup>
</p>
        <p>A associa&#xE7;&#xE3;o de DPI e uso dos agentes anti-TNF, em especial infliximabe e
etanercepte, j&#xE1; foi descrita.<sup>(</sup><xref rid="B02" ref-type="bibr"><sup>2</sup></xref><sup>)</sup> O adalimumabe &#xE9; a mais nova droga dessa classe e,
por ser um anticorpo monoclonal humanizado, teria a vantagem potencial de ser menos
imunog&#xEA;nico do que seus precursores. Contudo, apesar do uso incipiente, algumas
publica&#xE7;&#xF5;es sugerem que o adalimumabe pode determinar a indu&#xE7;&#xE3;o ou mesmo a
exacerba&#xE7;&#xE3;o de DPIs preexistentes.<sup>(</sup><xref rid="B03" ref-type="bibr"><sup>3</sup></xref><sup>-</sup><xref rid="B09" ref-type="bibr"><sup>9</sup></xref><sup>)</sup>
</p>
        <p>O objetivo do presente estudo foi relatar o primeiro caso brasileiro de DPI aguda
secund&#xE1;ria &#xE0; utiliza&#xE7;&#xE3;o de adalimumabe, em uma paciente portadora de AR sem DPI
pr&#xE9;via.</p>
      </sec>
      <sec>
        <title>Relato de caso</title>
        <p>Paciente do sexo feminino, 62 anos, com antecedente de AR h&#xE1; 20 anos, vinha em uso de
metotrexato, leflunomide e prednisona. Devido &#xE0; manuten&#xE7;&#xE3;o do quadro inflamat&#xF3;rio
articular, optou-se pela introdu&#xE7;&#xE3;o de adalimumabe, mantendo-se o metotrexato. A
radiografia de t&#xF3;rax n&#xE3;o demonstrava altera&#xE7;&#xF5;es sugestivas de tuberculose pr&#xE9;via ou
sinais de DPI incipiente; e a intradermorrea&#xE7;&#xE3;o para tuberculose (PPD) foi n&#xE3;o
reagente (0 mm). Uma semana ap&#xF3;s a segunda dose de adalimumabe (40 mg semanais), a
paciente iniciou um quadro de tosse seca, dispneia aos moderados esfor&#xE7;os e febre
di&#xE1;ria (38&#xB0;C). Naquele momento, a radiografia de t&#xF3;rax, o exame f&#xED;sico e os exames
laboratoriais, incluindo hemograma, eram normais - hemoglobina, 13,1 g/dL;
hemat&#xF3;crito, 39,2%; 8.380 leuc&#xF3;citos (75% neutr&#xF3;filos, 0,4% eosin&#xF3;filos, 9,8%
linf&#xF3;citos); e 355.000 plaquetas, exceto por um aumento dos marcadores inflamat&#xF3;rios
(prote&#xED;na C reativa, 326 mg/dL; valor de refer&#xEA;ncia &lt; 3 mg/dL) e na VHS (67 mm,
valor de refer&#xEA;ncia &lt; 20,2 mm). As pesquisas para BAAR no escarro e as
hemoculturas foram negativas. Foi iniciado o tratamento emp&#xED;rico com levofloxacina;
por&#xE9;m, a paciente manteve febre e dispneia. A TCAR de t&#xF3;rax, realizada duas semanas
ap&#xF3;s o in&#xED;cio dos sintomas, evidenciou opacidades em vidro fosco com predom&#xED;nio nos
campos superiores e m&#xE9;dios do pulm&#xE3;o, associadas a &#xE1;reas de espessamento liso dos
septos interlobulares (<xref ref-type="fig" rid="f03">Figura 1</xref>). Foi feita
ent&#xE3;o a hip&#xF3;tese diagn&#xF3;stica de DPI secund&#xE1;ria ao uso de adalimumabe. Optou-se pela
suspens&#xE3;o do agente anti-TNF e do metotrexato com manuten&#xE7;&#xE3;o de prednisona em baixa
dose (5 mg/dia). A paciente apresentou melhora progressiva da dispneia, remiss&#xE3;o da
febre e normaliza&#xE7;&#xE3;o dos marcadores inflamat&#xF3;rios, sem reativa&#xE7;&#xE3;o do quadro
articular. Tr&#xEA;s semanas ap&#xF3;s o in&#xED;cio do quadro, o exame f&#xED;sico e a espirometria eram
normais, com SpO<sub>2</sub> de 98% em ar ambiente. A nova TCAR realizada tr&#xEA;s
semanas ap&#xF3;s o in&#xED;cio dos sintomas mostrou resolu&#xE7;&#xE3;o quase completa das &#xE1;reas em
vidro fosco (<xref ref-type="fig" rid="f04">Figura 2</xref>).</p>
        <p>
<fig id="f03" orientation="portrait" position="float"><label>Figura 1</label><caption><title>TCAR de t&#xF3;rax evidenciando opacidades pulmonares em vidro fosco com
predom&#xED;nio pelos lobos superiores, em A, e pelas regi&#xF5;es centrais, em B,
associada a &#xE1;reas de espessamento liso dos septos interlobulares
(setas).</title></caption><graphic xlink:href="1806-3713-jbpneu-40-01-00077-gf01-pt"/></fig>
</p>
        <p>
<fig id="f04" orientation="portrait" position="float"><label>Figura 2</label><caption><title>TCAR de t&#xF3;rax realizada tr&#xEA;s semanas ap&#xF3;s o in&#xED;cio do quadro. A an&#xE1;lise
comparativa dos cortes mostra melhora importante e espont&#xE2;nea das opacidades
em vidro fosco com rela&#xE7;&#xE3;o ao exame anterior nos campos pulmonares
superiores, em A, e no n&#xED;vel da carina principal, em B. Restam discretas
opacidades em vidro fosco junto a um discreto infiltrado reticular em
regi&#xF5;es subpleurais com predom&#xED;nio no hemit&#xF3;rax direito, especialmente no
lobo m&#xE9;dio.</title></caption><graphic xlink:href="1806-3713-jbpneu-40-01-00077-gf02-pt"/></fig>
</p>
      </sec>
      <sec>
        <title>Discuss&#xE3;o</title>
        <p>A patog&#xEA;nese da les&#xE3;o pulmonar pelas terapias com agentes anti-TNF ainda &#xE9;
desconhecida; acredita-se que o TNF tenha uma a&#xE7;&#xE3;o pr&#xF3;-fibr&#xF3;tica ao estimular a
s&#xED;ntese de col&#xE1;geno por fibroblastos e miofibroblastos.<sup>(</sup><xref rid="B10" ref-type="bibr"><sup>10</sup></xref><sup>)</sup> Especula-se ainda que o
aumento da resposta linfocit&#xE1;ria do tipo Th2,<sup>(</sup><xref rid="B07" ref-type="bibr"><sup>7</sup></xref><sup>)</sup> a a&#xE7;&#xE3;o do IFN-&#x3B3; sem oposi&#xE7;&#xE3;o pelo
TNF<sup>(</sup><xref rid="B07" ref-type="bibr"><sup>7</sup></xref><sup>)</sup> e a
a&#xE7;&#xE3;o sin&#xE9;rgica do metotrexato possam ter um papel no desenvolvimento da les&#xE3;o
pulmonar.<sup>(</sup><xref rid="B08" ref-type="bibr"><sup>8</sup></xref><sup>,</sup><xref rid="B09" ref-type="bibr"><sup>9</sup></xref><sup>,</sup><xref rid="B11" ref-type="bibr"><sup>11</sup></xref><sup>,</sup><xref rid="B12" ref-type="bibr"><sup>12</sup></xref><sup>)</sup>
</p>
        <p>Os achados cl&#xED;nicos s&#xE3;o inespec&#xED;ficos, e incluem tosse seca, febre e
dispneia,<sup>(</sup><xref rid="B02" ref-type="bibr"><sup>2</sup></xref><sup>)</sup> que podem ser progressivas ou mais intensas ap&#xF3;s
cada aplica&#xE7;&#xE3;o da medica&#xE7;&#xE3;o.<sup>(</sup><xref rid="B06" ref-type="bibr"><sup>6</sup></xref><sup>)</sup> Os sintomas podem iniciar-se de um
m&#xEA;s<sup>(</sup><xref rid="B09" ref-type="bibr"><sup>9</sup></xref><sup>)</sup> at&#xE9;
tr&#xEA;s anos e meio ap&#xF3;s o in&#xED;cio do tratamento.<sup>(</sup><xref rid="B07" ref-type="bibr"><sup>7</sup></xref><sup>)</sup> &#xC0; TCAR, podem ser evidenciadas
opacidades em vidro fosco, focos de consolida&#xE7;&#xE3;o, padr&#xE3;o reticulado e
bronquiolectasias de tra&#xE7;&#xE3;o.<sup>(</sup><xref rid="B06" ref-type="bibr"><sup>6</sup></xref><sup>,</sup><xref rid="B08" ref-type="bibr"><sup>8</sup></xref><sup>)</sup>
</p>
        <p>A atribui&#xE7;&#xE3;o da les&#xE3;o pulmonar a drogas e, no presente caso, aos agentes anti-TNF &#xE9;
um desafio. O diagn&#xF3;stico &#xE9; geralmente presuntivo, e estabelece-se o nexo causal pela
associa&#xE7;&#xE3;o temporal entre a introdu&#xE7;&#xE3;o da droga com o in&#xED;cio dos sintomas e pela
melhora ap&#xF3;s sua suspens&#xE3;o, sempre ap&#xF3;s a exclus&#xE3;o de outras etiologias. Nesses
pacientes, no contexto de imunossupress&#xE3;o, deve-se considerar infec&#xE7;&#xE3;o como um
importante diferencial.<sup>(</sup><xref rid="B13" ref-type="bibr"><sup>13</sup></xref><sup>)</sup> Deve-se lembrar que h&#xE1; relatos da associa&#xE7;&#xE3;o
entre o uso de adalimumabe com casos de criptococose pulmonar<sup>(</sup><xref rid="B14" ref-type="bibr"><sup>14</sup></xref><sup>)</sup> e micobacteriose
disseminada.<sup>(</sup><xref rid="B15" ref-type="bibr"><sup>15</sup></xref><sup>)</sup> Nesse contexto cl&#xED;nico, opacidades em vidro
fosco difusas em associa&#xE7;&#xE3;o a espessamento septal intralobular tamb&#xE9;m devem suscitar
a exclus&#xE3;o de outras etiologias, como infec&#xE7;&#xF5;es virais ou por <italic>Pneumocystis
jiroveci</italic>,<sup>(</sup><xref rid="B16" ref-type="bibr"><sup>16</sup></xref><sup>)</sup> hemorragia alveolar, congest&#xE3;o pulmonar e
toxicidade a drogas pelo uso concomitante do metotrexato. A broncoscopia com lavado
broncoalveolar auxilia no diagn&#xF3;stico diferencial.</p>
        <p>Na maior casu&#xED;stica de pacientes com les&#xE3;o pulmonar secund&#xE1;ria ao uso de terapia
anti-TNF, foram relatados 122 casos (3 deles secund&#xE1;rios ao adalimumabe). O tempo
m&#xE9;dio para o aparecimento dos sintomas foi de 26 semanas. Os padr&#xF5;es histol&#xF3;gicos
mais comumente encontrados foram o de pneumonia intersticial usual, pneumonia
organizante, dano alveolar difuso e at&#xE9; pneumonia intersticial linfoc&#xED;tica. Nos casos
onde houve seguimento at&#xE9; o desfecho houve melhora da DPI em 40%, resolu&#xE7;&#xE3;o parcial
em 25% e nenhuma resolu&#xE7;&#xE3;o em 35%, com &#xF3;bito em 29% dos pacientes. Fatores preditores
para um pior progn&#xF3;stico foram idade &gt; 65 anos, surgimento tardio dos sintomas,
uso frequente de outros imunossupressores (principalmente o metotrexato) e
diagn&#xF3;stico pr&#xE9;vio de DPI.<sup>(</sup><xref rid="B02" ref-type="bibr"><sup>2</sup></xref><sup>)</sup> A despeito de um relato isolado de melhora da DPI
com o uso dessa medica&#xE7;&#xE3;o para AR,<sup>(</sup><xref rid="B09" ref-type="bibr"><sup>9</sup></xref><sup>)</sup> a recomenda&#xE7;&#xE3;o atual n&#xE3;o contraindica, mas
preconiza cautela quanto ao uso do adalimumabe e de outras drogas anti-TNF em
pacientes com DPI ou pneumopatias preexistentes.<sup>(</sup><xref rid="B01" ref-type="bibr"><sup>1</sup></xref><sup>-</sup><xref rid="B03" ref-type="bibr"><sup>3</sup></xref><sup>,</sup><xref rid="B10" ref-type="bibr"><sup>10</sup></xref><sup>)</sup>
</p>
        <p>A evolu&#xE7;&#xE3;o dos casos de DPI por adalimumabe &#xE9; vari&#xE1;vel, podendo ocorrer desde a
remiss&#xE3;o completa ap&#xF3;s a simples suspens&#xE3;o da droga at&#xE9; refratariedade aos
tratamentos empregados,<sup>(</sup><xref rid="B02" ref-type="bibr"><sup>2</sup></xref><sup>,</sup><xref rid="B06" ref-type="bibr"><sup>6</sup></xref><sup>)</sup> com r&#xE1;pida evolu&#xE7;&#xE3;o a &#xF3;bito.<sup>(</sup><xref rid="B03" ref-type="bibr"><sup>3</sup></xref><sup>)</sup> A utiliza&#xE7;&#xE3;o de
corticosteroides e/ou de imunoglobulina intravenosa deve ser considerada em casos
selecionados. Pela potencial gravidade do quadro, optamos pelo seguimento tomogr&#xE1;fico
com exames realizados em curto intervalo de tempo a despeito da carga de irradia&#xE7;&#xE3;o
com o exame de imagem.</p>
        <p>Uma vez constatada a rea&#xE7;&#xE3;o &#xE0; droga, n&#xE3;o se recomenda sua reintrodu&#xE7;&#xE3;o ou mesmo
substitui&#xE7;&#xE3;o por outro f&#xE1;rmaco pertencente &#xE0; mesma classe de agentes
anti-TNF.<sup>(</sup><xref rid="B02" ref-type="bibr"><sup>2</sup></xref><sup>,</sup><xref rid="B10" ref-type="bibr"><sup>10</sup></xref><sup>)</sup> Dessa forma, o adalimumabe, a exemplo de outras
drogas anti-TNF, tamb&#xE9;m deve ser considerado na listagem de drogas potencialmente
causadoras de les&#xE3;o pulmonar.</p>
      </sec>
    </body>
    <back>
      <fn-group>
        <fn id="fn02" fn-type="supported-by">
          <label>*</label>
          <p>Trabalho realizado na Divis&#xE3;o de Pneumologia, Instituto do Cora&#xE7;&#xE3;o, Hospital das
Cl&#xED;nicas, Faculdade de Medicina da Universidade de S&#xE3;o Paulo, S&#xE3;o Paulo (SP)
Brasil.</p>
        </fn>
      </fn-group>
    </back>
  </sub-article>
</article>
</pmc-articleset>
